- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06077643
Workshops and Exchange Groups for Laryngectomized Patients (GELAT)
This research is conducted with the aim of improving the quality of life of laryngectomized patients and their entourage. Worldwide, there are 185,000 new cases of laryngeal cancer per year. In Europe, between 2000 and 2007, the crude annual incidence rates of these cancers were 4.6/100,000 with a 5-year survival rate of 61%.
In France, about 30 to 35% of cancers of the upper aerodigestive tract are localized to the larynx, or about 43,000 cases per year. Most patients are men (89%) between 50 and 70 years old. One of the treatments for these cancers is to perform an excision of the larynx thus removing the entire tumor, it is the total laryngectomy. The trachea is thus permanently removed from the skin and the digestive tract becomes independent.
Study Overview
Status
Conditions
Detailed Description
In the ENT department of Bichat Hospital, there is an average of fourteen surgeries of this type per year, over the last three years. The direct consequences of total laryngectomy are multiple:
- loss of phonation (voice) and need to learn to speak again through speech therapy;
- Disappearance of oral-nasal breathing (and therefore loss of smell, or even taste);
- Disappearance of the capacity of the effort with closed glottis (used in the acts of daily life: defecation, sexual act in men, etc.);
- Impairment of body image and sometimes self-esteem.
For these reasons, it is essential to accompany patients post-operative to help them understand their body image and mitigate the direct and indirect consequences of this intervention. There are very few organizations to assist these patients in this life change.
To support laryngectomized patients, the study will test and validate the creation of self-help and support groups. The study will include laryngectomized patients who wish and can participate in these groups.
The sessions will take place as follows:
- 1st: presentation of each, answers to questions;
- 2nd: intervention of the association of the mutilated of the voice;
- 3rd: questions / answers with a resource patient (laryngectomized for 13 years in Bichat);
- 4th: grouping of all participants to assess patient satisfaction.
To assess the benefit of these meetings, a global quality of life questionnaire (WHOQOL-BREF) and an ENT-specific questionnaire (EORTC QLQH&n43) will be given to patients before the first session and retrieved beforehand. The patient will be able to participate in the sessions only if the questionnaires are submitted. The questionnaires are accompanied by a free text part, so that the person fills in the keys that the workshops have brought him. Patients who cannot participate in the exchange groups for geographical or personal reasons will constitute a control group. They will also complete the two questionnaires four months apart. The number of patients registered and the participation rate at each session will be evaluated.
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Angèle Germon
- Phone Number: 06.40.65.58.75
- Email: angele.germon@aphp.fr
Study Contact Backup
- Name: Diane Evrard, MD
- Phone Number: 01.40.25.77.14
- Email: diane.evrard@aphp.fr
Study Locations
-
-
-
Paris, France, 75018
- Recruiting
- Bichat - Claude Bernard Hospital
-
Contact:
- Angèle Germon
- Phone Number: 06.40.65.58.75
- Email: angele.germon@aphp.fr
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Have had a total laryngectomy at Bichat Hospital or HEGP within the last four years
- Have completed all the specific care of the pathology that required the total laryngectomy
- Be able to travel to Bichat Hospital for all four sessions
- Be over 18 years of age
- Have received informed information about the conduct of the research.
Exclusion Criteria:
- WHO simplified autonomy scale greater than 2, i.e. from normal activity to ambulant and able to take care of themselves, but unable to provide work and bedridden for less than 50% of their time
- Patient who does not speak or understand French
- Lack of affiliation to a social security scheme or CMU
- Patient benefiting from legal protection measures (guardianship or curatorship)
- Patient who has communicated an objection to their inclusion, after informed information.
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
|---|
|
Exchange group
Each patient will participate in a cycle of four sessions, over four months.
Each will be carried out with five patients, in order to facilitate exchanges.
The aim is to organize eight groups that will each complete a cycle.
This will allow to include about forty patients in the study.
|
|
Control group
Patients who don't want to participate in the exchange groups but agree to be included in the control group. They will have to complete the quality of life questionnaires four months apart. Estimation of 10 patients included. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Differences in quality of life scores before and after the program, between the program and non-program control groups.
Time Frame: 4 months
|
The aim is to show a difference in patients' overall quality of life scores via the WHOQOL-BREF questionnaire, before and after the program.
|
4 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
For overall quality of life using the WHOQOL-BREF questionnaire, comparison of the average patient scores, before and after exchange groups.
Time Frame: 4 months
|
The aim is to show a difference in patients' overall quality of life scores via the WHOQOL-BREF questionnaire, before and after the program.
|
4 months
|
|
For ENT-specific quality of life using the EORTC QLQH&n43 questionnaire, comparison of the average patient scores, before and after exchange groups.
Time Frame: 4 months
|
The aim is to show a difference in quality of life scores specific to ENT EORTC QLQH&n43, before and after the program.
|
4 months
|
|
Evaluation of the participation rate (number of patients present out of the number of patients enrolled), during each session via the OVET software.
Time Frame: 4 months
|
4 months
|
Collaborators and Investigators
Investigators
- Principal Investigator: Angèle Germon, Assistance Publique Hopitaux De Paris
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- APHP230743
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Laryngeal Cancer
-
University Hospital OstravaRecruitingLaryngeal Disease | Laryngeal Lesions | Hypopharyngeal Lesions | Suspected Laryngeal Cancer | Suspected Hypopharyngeal Cancer | Proven Laryngeal Cancer | Proven Hypopharyngeal CancerCzechia
-
Thomas Jefferson UniversityCompletedHead and Neck Carcinoma | Lung Carcinoma | Oral Cavity Carcinoma | Paranasal Sinus Carcinoma | Stage III Laryngeal Cancer AJCC v8 | Stage IV Laryngeal Cancer AJCC v8 | Hypopharyngeal Carcinoma | Laryngeal Carcinoma | Stage IVA Laryngeal Cancer AJCC v8 | Stage IVB Laryngeal Cancer AJCC v8 | Stage IVC Laryngeal... and other conditionsUnited States
-
Wake Forest University Health SciencesTerminatedHead and Neck Cancer | Stage I Laryngeal Cancer | Stage II Laryngeal Cancer | Stage I Hypopharyngeal Cancer | Stage I Oropharyngeal Cancer | Stage II Hypopharyngeal Cancer | Stage II Oropharyngeal Cancer | Stage III Hypopharyngeal Cancer | Stage III Laryngeal Cancer | Stage III Oropharyngeal Cancer | Stage... and other conditionsUnited States
-
Humanitas UniversityEnrolling by invitationLaryngeal Cancer | Laryngeal CarcinomaItaly
-
Centre Hospitalier Universitaire de NīmesCompleted
-
The Affiliated Nanjing Drum Tower Hospital of Nanjing...Zhongda Hospital; Nanjing Children's Hospital; Shanghai Ninth People's Hospital... and other collaboratorsNot yet recruitingHead and Neck Cancer | Laryngeal Cancer | Hypopharyngeal CancerChina
-
Eye & ENT Hospital of Fudan UniversityNot yet recruitingLaryngeal Cancer | Difficult Airway
-
The Netherlands Cancer InstituteAstraZenecaActive, not recruitingHead and Neck Neoplasms | Carcinoma, Squamous Cell | Laryngeal Cancer Stage II | Laryngeal Cancer Stage IIINetherlands
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingStage III Laryngeal Cancer AJCC v8 | Laryngeal Squamous Cell Carcinoma | Stage II Laryngeal Cancer AJCC v8United States
-
First Affiliated Hospital, Sun Yat-Sen UniversityUnknownRecurrent Laryngeal CancerChina